JP2017510645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510645A5 JP2017510645A5 JP2017502942A JP2017502942A JP2017510645A5 JP 2017510645 A5 JP2017510645 A5 JP 2017510645A5 JP 2017502942 A JP2017502942 A JP 2017502942A JP 2017502942 A JP2017502942 A JP 2017502942A JP 2017510645 A5 JP2017510645 A5 JP 2017510645A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutical composition
- composition according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001408 amides Chemical class 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- -1 cyano, formyl Chemical group 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 2
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims 2
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 150000003053 piperidines Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- FJUKOXWSIGULLE-JVOQCOEYSA-N (2r)-4-oxo-2-[(3s,4r)-2-oxo-3-[(4s)-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]-4-[(e)-2-phenylethenyl]azetidin-1-yl]-n-[(1r)-1-phenylethyl]-4-(4-piperidin-1-ylpiperidin-1-yl)butanamide Chemical compound C([C@H](C(=O)N[C@H](C)C=1C=CC=CC=1)N1C([C@@H](N2C(OC[C@@H]2C=2C=CC=CC=2)=O)[C@H]1\C=C\C=1C=CC=CC=1)=O)C(=O)N(CC1)CCC1N1CCCCC1 FJUKOXWSIGULLE-JVOQCOEYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical group SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 1
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical class NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077195A JP2022116001A (ja) | 2014-03-28 | 2022-05-09 | 神経変性疾患を治療するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461971862P | 2014-03-28 | 2014-03-28 | |
| US61/971,862 | 2014-03-28 | ||
| PCT/US2015/023060 WO2015148962A1 (en) | 2014-03-28 | 2015-03-27 | Compositions and methods for treating neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077195A Division JP2022116001A (ja) | 2014-03-28 | 2022-05-09 | 神経変性疾患を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510645A JP2017510645A (ja) | 2017-04-13 |
| JP2017510645A5 true JP2017510645A5 (enExample) | 2018-05-17 |
| JP7255967B2 JP7255967B2 (ja) | 2023-04-11 |
Family
ID=54196457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502942A Active JP7255967B2 (ja) | 2014-03-28 | 2015-03-27 | 神経変性疾患を治療するための組成物および方法 |
| JP2022077195A Pending JP2022116001A (ja) | 2014-03-28 | 2022-05-09 | 神経変性疾患を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077195A Pending JP2022116001A (ja) | 2014-03-28 | 2022-05-09 | 神経変性疾患を治療するための組成物および方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9802925B2 (enExample) |
| EP (1) | EP3122743B1 (enExample) |
| JP (2) | JP7255967B2 (enExample) |
| KR (2) | KR20160130853A (enExample) |
| CN (3) | CN116139282A (enExample) |
| AU (2) | AU2015237253B2 (enExample) |
| BR (1) | BR112016022575A2 (enExample) |
| CA (1) | CA2944211C (enExample) |
| DK (1) | DK3122743T3 (enExample) |
| ES (1) | ES2939959T3 (enExample) |
| FI (1) | FI3122743T3 (enExample) |
| IL (1) | IL248074B (enExample) |
| MX (2) | MX2021005502A (enExample) |
| MY (1) | MY184878A (enExample) |
| NZ (1) | NZ724718A (enExample) |
| PL (1) | PL3122743T3 (enExample) |
| RU (1) | RU2742773C2 (enExample) |
| SG (2) | SG11201608064WA (enExample) |
| SI (1) | SI3122743T1 (enExample) |
| TW (2) | TWI736519B (enExample) |
| WO (1) | WO2015148962A1 (enExample) |
| ZA (1) | ZA201606673B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2662350T3 (es) | 2010-07-01 | 2018-04-06 | Azevan Pharmaceuticals, Inc. | Procedimientos para el tratamiento del trastorno por estrés postraumático |
| KR20160130853A (ko) * | 2014-03-28 | 2016-11-14 | 아제반 파마슈티칼스, 인코퍼레이티드 | 신경변성 질환을 치료하기 조성물 및 방법 |
| TWI622380B (zh) * | 2017-01-17 | 2018-05-01 | 正崴精密工業股份有限公司 | 生理訊號測量裝置及其血氧濃度演算方法 |
| AU2018333051B2 (en) | 2017-09-15 | 2024-03-21 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating brain injury |
| EP4267117A4 (en) * | 2020-12-23 | 2024-12-11 | Celgene Corporation | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases |
| WO2023164710A1 (en) * | 2022-02-28 | 2023-08-31 | The Trustees Of Columbia University In The City Of New York | Avpr1a blockade to reduce social isolation-induced anxiety in females |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS6033439B2 (ja) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
| FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
| US4665171A (en) | 1985-07-17 | 1987-05-12 | Harvard University | Process and intermediates for β-lactam antibiotics |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
| US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| CA2093125C (en) | 1990-10-02 | 2003-12-16 | Warner-Lambert Company | Angiotensin ii antagonists |
| GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5612336A (en) | 1992-07-13 | 1997-03-18 | Merck, Sharp & Dohme Ltd. | Heterocyclic amide derivatives as tachykinin antagonists |
| NZ255721A (en) | 1992-08-13 | 1997-06-24 | Warner Lambert Co | Hetarylmethoxy carbonyl substituted tryptophan amides, esters, analogues and pharmaceutical compositions thereof |
| FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| DE69405862T2 (de) | 1993-05-06 | 1998-01-15 | Merrell Pharma Inc | Substituierte pyrrolidin-3-alkyl-piperidine verwendbar als tachykinin-antagonisten |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| WO1997030707A1 (en) | 1996-02-23 | 1997-08-28 | Eli Lilly And Company | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS |
| ES2229525T3 (es) | 1997-07-30 | 2005-04-16 | Wyeth | Agonistas triciclicos de la vasopresina. |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| BR9812772A (pt) | 1997-10-27 | 2000-10-10 | Reddy Research Foundation | "compostos tricìclicos inéditos e o seu emprego na medicina;processo para a sua preparação e composições farmacêuticas contendo os mesmos" |
| MXPA02001667A (es) | 1999-08-16 | 2003-07-14 | Revaax Pharmaceuticals Llc | Composicion y metodo neuroterapeutico. |
| GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| EP1434763B1 (en) | 2001-10-12 | 2018-01-17 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin v1a antagonists |
| WO2003051314A2 (en) | 2001-12-18 | 2003-06-26 | Medallion Biomedical, Llc | Antibiotic compounds |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| GB0224919D0 (en) * | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| TW200526651A (en) | 2003-10-03 | 2005-08-16 | Serenix Pharmaceuticals Llc | 3-substituted β-lactamyl vasopressin V1a antagonists |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| EP1669776A1 (de) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät |
| FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
| JP2008534504A (ja) * | 2005-03-22 | 2008-08-28 | アゼヴァン ファーマスーティカルズ，インコーポレイテッド | 月経前障害を治療するためのβラクタミルアルカン酸 |
| WO2006123242A1 (en) | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| CN101268068B (zh) * | 2005-07-19 | 2015-12-02 | 阿泽范药品公司 | β-内酰胺基苯丙氨酸、半胱氨酸和丝氨酸血管加压素拮抗剂 |
| WO2007109615A2 (en) * | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
| US20100016274A1 (en) | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
| AU2007299822A1 (en) | 2006-09-22 | 2008-03-27 | Janssen Pharmaceutica N.V. | Spiro benzazepines as vasopressin antagonists |
| CA2681695A1 (en) | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| US20090182011A1 (en) * | 2008-01-16 | 2009-07-16 | University Of Illinois Chicago | Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression |
| FR2927625B1 (fr) * | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
| FR2930249B1 (fr) | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
| ES2662350T3 (es) * | 2010-07-01 | 2018-04-06 | Azevan Pharmaceuticals, Inc. | Procedimientos para el tratamiento del trastorno por estrés postraumático |
| JP2016513112A (ja) | 2013-02-18 | 2016-05-12 | ザ スクリプス リサーチ インスティテュート | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
| KR20160130853A (ko) | 2014-03-28 | 2016-11-14 | 아제반 파마슈티칼스, 인코퍼레이티드 | 신경변성 질환을 치료하기 조성물 및 방법 |
| AU2018333051B2 (en) | 2017-09-15 | 2024-03-21 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating brain injury |
-
2015
- 2015-03-27 KR KR1020167028877A patent/KR20160130853A/ko not_active Ceased
- 2015-03-27 MY MYPI2016703577A patent/MY184878A/en unknown
- 2015-03-27 DK DK15769990.1T patent/DK3122743T3/da active
- 2015-03-27 CN CN202310338451.5A patent/CN116139282A/zh active Pending
- 2015-03-27 BR BR112016022575A patent/BR112016022575A2/pt not_active Application Discontinuation
- 2015-03-27 JP JP2017502942A patent/JP7255967B2/ja active Active
- 2015-03-27 ES ES15769990T patent/ES2939959T3/es active Active
- 2015-03-27 EP EP15769990.1A patent/EP3122743B1/en active Active
- 2015-03-27 CN CN201580027324.7A patent/CN106459021B/zh active Active
- 2015-03-27 SG SG11201608064WA patent/SG11201608064WA/en unknown
- 2015-03-27 KR KR1020227038057A patent/KR102725123B1/ko active Active
- 2015-03-27 SI SI201531921T patent/SI3122743T1/sl unknown
- 2015-03-27 RU RU2016138349A patent/RU2742773C2/ru active
- 2015-03-27 WO PCT/US2015/023060 patent/WO2015148962A1/en not_active Ceased
- 2015-03-27 CA CA2944211A patent/CA2944211C/en active Active
- 2015-03-27 AU AU2015237253A patent/AU2015237253B2/en active Active
- 2015-03-27 US US15/129,190 patent/US9802925B2/en active Active
- 2015-03-27 NZ NZ724718A patent/NZ724718A/en unknown
- 2015-03-27 SG SG10202001065SA patent/SG10202001065SA/en unknown
- 2015-03-27 FI FIEP15769990.1T patent/FI3122743T3/fi active
- 2015-03-27 MX MX2021005502A patent/MX2021005502A/es unknown
- 2015-03-27 CN CN202310338535.9A patent/CN116327950A/zh active Pending
- 2015-03-27 PL PL15769990.1T patent/PL3122743T3/pl unknown
- 2015-03-27 MX MX2016012645A patent/MX382453B/es unknown
- 2015-03-30 TW TW104110388A patent/TWI736519B/zh active
- 2015-03-30 TW TW110125694A patent/TWI839623B/zh active
-
2016
- 2016-09-27 IL IL248074A patent/IL248074B/en active IP Right Grant
- 2016-09-27 ZA ZA2016/06673A patent/ZA201606673B/en unknown
-
2017
- 2017-10-18 US US15/786,772 patent/US10364236B2/en active Active
-
2019
- 2019-06-10 US US16/436,350 patent/US11319306B2/en active Active
- 2019-10-23 AU AU2019253831A patent/AU2019253831B2/en active Active
-
2022
- 2022-04-29 US US17/732,631 patent/US20230123729A1/en not_active Abandoned
- 2022-05-09 JP JP2022077195A patent/JP2022116001A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510645A5 (enExample) | ||
| MX2019002212A (es) | Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos. | |
| SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
| MX2020002060A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| JP2020502092A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| JP2020534274A5 (enExample) | ||
| RU2016138349A (ru) | Композиции и способы лечения нейродегенеративных заболеваний | |
| TW200628154A (en) | Organic compounds | |
| JP2012513416A5 (enExample) | ||
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| JP2019535723A5 (enExample) | ||
| JP2016513681A5 (enExample) | ||
| MX2010001005A (es) | Derivados de (hetero)aril-metilen-n-cicloalquilcarboxamida condensados de 6 elementos con n como fungicidas. | |
| JP2016529319A5 (enExample) | ||
| CY1113622T1 (el) | Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης | |
| JP2016500653A5 (enExample) | ||
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| AR078120A1 (es) | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas | |
| JP2016537396A5 (enExample) |